This treatment is intended for decompensated cirrhosis patients. About 30 ml of bone marrow fluid will be collected from about 10 patients, cultured for about three weeks to increase bone marrow mesenchymal stem cells, and then intravenously drip-infused in the patients’ vein. PI is Professor Sakai.
JST news release, August 6, 2014
Yamaguchi University starts clinical tests on autologous bone marrow cell therapy (ABMi) for treatment of liver cirrhosis